Weilizhibo-B (09887): LBL-047 was used as the first subject in the Phase I trial

According to the Zhitong Finance App, Weilizhibo-B (09887) issued an announcement to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and initial clinical efficacy of LBL-047.

This phase I study is a randomized, double-blind, placebo-controlled, single-dose escalation trial in healthy adults and systemic lupus erythematosus (SLE) patients to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics and initial clinical efficacy of LBL-047. Professor Meng Xianmin of the Shanghai Public Health Clinical Center was the main researcher for the health volunteer portion of the study, while Professor Ye Shuang and Professor Chen Sheng of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine were the main researchers in the SLE section.

LBL-047 is a bispecific fusion protein composed of a humanized anti-hemorrhagic dendritic cell antigen 2 (BDCA2) antibody and a modified transmembrane activator and calciclophilin ligand interacting molecule (TACI) extracellular domain. It blocks B-cell activation, differentiation, and antibody production by selectively removing pDC to reduce the production of type 1 interferon, and inhibit B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) signaling pathways. By targeting two major drivers of autoimmune disease pathogenesis, this differentiated approach has the potential to treat various autoimmune indications. In addition, LBL-047 has also been optimized to extend its half-life through Fc zone modification.